Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics

Merck Acquires Acceleron Pharma for $11.5 Billion

September 30, 2021

Biotechnology

Merck has entered into a definitive agreement to acquire Acceleron Pharma Inc. for $180 per share in cash, representing an approximate total equity value of $11.5 billion. The acquisition brings Acceleron's late-stage sotatercept program (for pulmonary arterial hypertension) and its REBLOZYL portfolio into Merck's cardiovascular pipeline, subject to tender offer completion and customary regulatory approvals.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

Merck Acquires Pandion Therapeutics

February 25, 2021

Biotechnology

Merck will acquire Pandion Therapeutics for $60 per share in cash, representing an approximate total equity value of $1.85 billion, via a tender offer and subsequent merger. Pandion is a clinical-stage biotechnology company focused on precision immune modulators (TALON platform) with lead candidate PT101 targeting regulatory T cells for autoimmune diseases; the transaction is expected to close in the first half of 2021 subject to customary conditions.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva, Inc. agreed to acquire all outstanding shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis' equity at approximately $113 million on a fully diluted basis. The transaction makes Entasis a wholly owned subsidiary of Innoviva and advances Innoviva's strategy to expand into differentiated late-stage biopharmaceutical assets, including Entasis' lead antibacterial candidate SUL-DUR.

BridgeBio Pharma Acquires Remaining Shares of Eidos Therapeutics

October 5, 2020

Biotechnology

BridgeBio Pharma agreed to acquire all outstanding shares of Eidos Therapeutics that it does not already own, offering Eidos shareholders the choice of 1.85 BridgeBio shares or cash (up to a $175 million aggregate cash cap). The transaction reunites Eidos and its lead candidate acoramidis with BridgeBio’s clinical development and commercial infrastructure to accelerate development and potential global launch of the therapy for ATTR.

AstraZeneca Acquires Fusion Pharmaceuticals

March 19, 2024

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.